Thomas A. Waldmann

Thomas Waldmann Thomas A. Waldmann (21 September 1930 – 25 September 2021) was an American immunologist who has worked on therapeutic monoclonal antibodies to the IL-2 receptor, Interleukin 15 (IL-15), and Adult T-cell Leukemia (ATL). Until the week he died, he was an active distinguished investigator at the Lymphoid Malignancies Branch of the National Cancer Institute. Provided by Wikipedia
Showing 1 - 14 results of 14 for search 'Thomas A. Waldmann', query time: 0.04s Refine Results
  1. 1
    Making discoveries in immunology

    Making discoveries in immunology by Thomas A. Waldmann

    Published 2019-02-01
    Get full text
    Article
  2. 2
    Loss of cytotoxicity and gain of cytokine production in murine tumor-activated NK cells.

    Loss of cytotoxicity and gain of cytokine production in murine tumor-activated NK cells. by Jürgen R Müller, Thomas A Waldmann, Sigrid Dubois

    Published 2014-01-01
    Get full text
    Article
  3. 3
    Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink

    Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink by John A. Hangasky, Thomas A. Waldmann, Daniel V. Santi

    Published 2020-08-01
    Get full text
    Article
  4. 4
    IL-15 in the Combination Immunotherapy of Cancer

    IL-15 in the Combination Immunotherapy of Cancer by Thomas A. Waldmann, Sigrid Dubois, Milos D. Miljkovic, Kevin C. Conlon

    Published 2020-05-01
    Get full text
    Article
  5. 5
    Interleukin-15 Constrains Mucosal T Helper 17 Cell Generation: Influence of Mononuclear Phagocytes.

    Interleukin-15 Constrains Mucosal T Helper 17 Cell Generation: Influence of Mononuclear Phagocytes. by Huifeng Yu, Yongjun Sui, Yichuan Wang, Noriko Sato, Blake Frey, Zheng Xia, Thomas A Waldmann, Jay Berzofsky

    Published 2015-01-01
    Get full text
    Article
  6. 6
    Detection of Lymph Node Involvement in Hematologic Malignancies Using Micromagnetic Resonance Lymphangiography with a Gadolinum-Labeled Dendrimer Nanoparticle

    Detection of Lymph Node Involvement in Hematologic Malignancies Using Micromagnetic Resonance Lymphangiography with a Gadolinum-Labeled Dendrimer Nanoparticle by Hisataka Kobayashi, Satomi Kawamoto, Martin W. Brechbiel, Marcelino Bernardo, Noriko Sato, Thomas A. Waldmann, Yutaka Tagaya, Peter L. Choyke

    Published 2005-11-01
    Get full text
    Article
  7. 7
    A very long-acting IL-15: implications for the immunotherapy of cancer

    A very long-acting IL-15: implications for the immunotherapy of cancer by Wei Chen, Thomas A Waldmann, Anusara Daenthanasanmak, Sigrid P Dubois, Jürgen R Müller, John A Hangasky, Ralph Reid, Daniel V Santi

    Published 2022-01-01
    Get full text
    Article
  8. 8
    Clinical trial of a humanized anti‐IL‐2/IL‐15 receptor β chain in HAM/TSP

    Clinical trial of a humanized anti‐IL‐2/IL‐15 receptor β chain in HAM/TSP by Yoshimi Enose‐Akahata, Unsong Oh, Joan Ohayon, Bridgette Jeanne Billioux, Raya Massoud, Bonita R. Bryant, Ashley Vellucci, Nyater Ngouth, Irene Cortese, Thomas A. Waldmann, Steven Jacobson

    Published 2019-08-01
    Get full text
    Article
  9. 9
    Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia

    Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia by Anusara Daenthanasanmak, Yuquan Lin, Meili Zhang, Bonita R. Bryant, Michael N. Petrus, Richard N. Bamford, Craig J. Thomas, Milos D. Miljkovic, Kevin C. Conlon, Thomas A. Waldmann

    Published 2021-01-01
    Get full text
    Article
  10. 10
    Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies

    Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies by Thomas A Waldmann, Kevin C Conlon, Sigrid P Dubois, Milos D Miljkovic, Thomas A Fleisher, Stefania Pittaluga, Jennifer Hsu-Albert, Bonita R Bryant, Michael N Petrus, Liyanage P Perera, Jürgen R Müller, Joanna H Shih

    Published 2021-04-01
    Get full text
    Article
  11. 11
    First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia

    First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia by Sarah Cooley, Fiona He, Veronika Bachanova, Gregory M. Vercellotti, Todd E. DeFor, Julie M. Curtsinger, Paul Robertson, Bartosz Grzywacz, Kevin C. Conlon, Thomas A. Waldmann, David H. McKenna, Bruce R. Blazar, Daniel J. Weisdorf, Jeffrey S. Miller

    Published 2019-07-01
    Get full text
    Article
  12. 12
    Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases

    Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases by Marcia Bellon, Izabela Bialuk, Veronica Galli, Xue-Tao Bai, Lourdes Farre, Achilea Bittencourt, Ambroise Marçais, Michael N. Petrus, Lee Ratner, Thomas A. Waldmann, Vahid Asnafi, Antoine Gessain, Masao Matsuoka, Genoveffa Franchini, Olivier Hermine, Toshiki Watanabe, Christophe Nicot

    Published 2021-06-01
    Get full text
    Article
  13. 13
    Co-expression of Interleukin-15 Enhances the Protective Immune Responses Induced by Immunization with a Murine Malaria MVA-Based Vaccine Encoding the Circumsporozoite Protein.

    Co-expression of Interleukin-15 Enhances the Protective Immune Responses Induced by Immunization with a Murine Malaria MVA-Based Vaccine Encoding the Circumsporozoite Protein. by Marcela Parra, Xia Liu, Steven C Derrick, Amy Yang, Alvaro Molina-Cruz, Carolina Barillas-Mury, Hong Zheng, Phuong Thao Pham, Martha Sedegah, Arnel Belmonte, Dianne D Litilit, Thomas A Waldmann, Sanjai Kumar, Sheldon L Morris, Liyanage P Perera

    Published 2015-01-01
    Get full text
    Article
  14. 14
    Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

    Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors by Kevin Conlon, Douglas G McNeel, John A Thompson, Sema Kurtulus, Rom Leidner, Thomas A Waldmann, Andrea Wang-Gillam, William D Figg, Sumati Gupta, Cristina Bergamaschi, George N Pavlakis, Antonio Valentin, Barbara K Felber, Mario Roederer, Dionysios C Watson, Cody J Peer, E Lake Potter, Nehal S Parikh, Debby Long, Lang Ho Lee, Niladri Roy Chowdhury, Florent Bender

    Published 2021-11-01
    Get full text
    Article

Search Tools: